Advertise

Digital marketing that delivers

We are authentic, creative, driven, and have a passion to see our brand grow just as much as our clients.

These are the types of relationships that breed success.

HelloCare has spent the best part of the last decade capturing the hearts and minds of those within the aged care sector through a unique blend of informative and entertaining aged care content, and we would like to extend an invitation of opportunity to those wishing to utilise the strength of our platform and share their ideas and services with the world. 

We like to have fun, but we also take our role very seriously. 

There is a weight of responsibility that comes when dealing with society’s most vulnerable, especially when you consider just how small their representation is within mainstream media and social conversation.

Our relationship with our audience is one that was built on trust, and this trust has resulted in a bond with our loyal readers that can influence trends and insight into behavioural change.

If you want to get your brand out there, then get in contact with us at advertising@hellocare.com.au

Advertisement
Advertisement

Local training is the best long-term solution to Australia’s skills shortages – not increased migration

This significant rise in training may not satisfy those who want a quick solution to the skills shortages. But growth in Australia’s vocational education and training sector is a more sustainable way of filling the gaps. Read More

PM reminds providers that visitor restrictions don’t mean lockdown

Australia’s prime minister and some in the aged care industry appear to be at odds over one of the most contentious issues of the COVID-19 pandemic – how to protect the elderly, the most vulnerable members of the community during this crisis. Though united in their mission to keep older Australians safe, the government and... Read More

Australians in trial of “amazing” new drug said to halt Alzheimer’s

A new drug that could halt the progress of early-stage Alzheimer’s Disease is being assessed by the US drug regulator. Read More
Advertisement
Exit mobile version